Ivabradin Abz (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a lower resting heart rate while preserving myocardial contractility and blood pressure.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition and tolerance. The prescriber determines the starting dose, any titration steps, and the maintenance regimen according to current therapeutic guidelines.

Safety of ivabradine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless no suitable alternatives exist.

To place an order, submit an enquiry on the Ivabradin Abz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on beta‑adrenergic receptors and can reduce contractility and cause bronchospasm, making ivabradine a useful alternative when those effects are undesirable.

Store Ivabradin Abz at room temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and avoid exposure to excessive heat or humidity to maintain product stability.

Ivabradin Abz is taken orally as prescribed. The tablets should be swallowed whole with water, typically with or without food, according to the dosing schedule set by the treating physician.

The most serious adverse events include severe bradycardia (resting heart rate < 50 bpm), atrial fibrillation, symptomatic hypotension, and persistent visual disturbances such as retinal abnormalities. Patients should be monitored closely for these events, especially during dose initiation and titration.

Ivabradin Abz is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, resting heart rate below 50 bpm, acute decompensated heart failure, or in those taking strong CYP3A4 inhibitors that cannot be discontinued.